Delisting from Euronext Paris

Sinclair IS Pharma PLC

27 June 2013

Delisting from Euronext Paris

Sinclair IS Pharma plc (AIM: SPH.L), ("Sinclair IS" or "the Company") the international specialty pharmaceutical company announces that following a request by the Company the Board of Euronext Paris has agreed to the delisting of the Company's shares from Euronext Paris. In order to enable the Company's shareholders to sell their shares should they so wish, an orderly market withdrawal procedure from the French market will be put in place which will be operated via BNP Paribas Securities Services as centralising agent, this orderly market procedure will be available to shareholders wishing to utilise it between 28 June 2013 and 10 July 2013 and 17 July 2013 and 30 July 2013. It is expected that the delisting process from Euronext Paris will be completed on 12 August 2013.

The Board of Sinclair IS has decided that given the very low trading volumes on Euronext Paris, less than 3% in the first quarter of 2013, and in line with the Company's policy of reducing business complexity that maintaining the Euronext listing is no longer warranted. The Company's AIM listing will remain unaffected by this delisting process.

Ends

For further information please contact:

Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Robert Taylor

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Vijay Barathan

Notes to Editors:

About Sinclair IS Pharma plc - www.sinclairispharma.com

Sinclair IS Pharma is an international specialty pharmaceutical company centred on Dermatology; in particular Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.